Skip to main content

Table 1 AWG study sites and related IPTi Consortium projects

From: Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings

Site Study design Drug and regimens
Kenya, Asembo (Rarieda district) Randomized controlled trial SP + 3 days of artesunate (AS) 3 days of amodiaquine (AQ)+AS, 3 days of chlorproguanil-dapsone (CD), or 3 days of placebo; all arms with daily iron supplementation from 2 to 6.5 months of age
Day 1 dose of study drugs provided at 10, and 14 weeks and 9 months EPI visit. On day 2 and 3 the drug was administered in the home under supervision by compliance monitors. Follow-up to 24 months
North-eastern Tanzania, Korogwe and Same districts   SP
Mefloquine (MQ)
3 days of CD, or 3 days of placebo.
The drugs were administered at 3, 4 and 9 months, with the first dose of the drug administered under supervision at the clinic and the 2nd and 3rd dose at home unsupervised. Follow-up until 24 months.
Gabon, Lambaréné   SP or placebo was administered at 3, 9, and 15 months, follow-up until 30 months of age.
Ghana (Navrongo), Bawku, Kassena-Nankana, Bolgatanga and Builsa districts Implementation study SP at the time of PENTA 2, PENTA 3 and measles vaccinations administered at 2 months, 3 months and 9 months respectively.
Malawi, Lilongwe and Salima   SP was administered at the time of DPT2 (10 weeks), DPT3 (14 weeks) and measles vaccinations (9 months).
  1. SP – Sulphadoxine-Pyrimethamine
  2. AS – Artesunate
  3. AQ – Amodiaquine
  4. CD – Chlorproguanil-Dapsone
  5. MQ – Mefloquine
  6. DPT – Diphtheria, Pertussis, Tetanus
  7. PENTA – DPT, HepB, Hib